Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has a cash flow conversion efficiency ratio of 0.059x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.10 Billion ≈ $2.45 Billion USD) by net assets (€35.38 Billion ≈ $41.36 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GU5 liabilities breakdown for a breakdown of total debt and financial obligations.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Kan Specialities Material Co Ltd
SHE:002012
|
-0.009x |
|
Doubleview Gold Corp
V:DBG
|
0.003x |
|
Soft-World International
TWO:5478
|
-0.010x |
|
Zhejiang Golden Eagle Co Ltd
SHG:600232
|
0.006x |
|
Golden Eagle Energy Tbk
JK:SMMT
|
0.000x |
|
Daodaoquan Grain and Oil Co Ltd
SHE:002852
|
0.035x |
|
Panoro Energy ASA
OL:PEN
|
0.140x |
|
Csd Water Service Co Ltd
SHG:603903
|
0.098x |
Annual Cash Flow Conversion Efficiency for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2024)
The table below shows the annual cash flow conversion efficiency of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see GU5 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €37.77 Billion ≈ $44.16 Billion |
€3.44 Billion ≈ $4.02 Billion |
0.091x | -18.54% |
| 2023-12-31 | €36.68 Billion ≈ $42.88 Billion |
€4.10 Billion ≈ $4.80 Billion |
0.112x | -46.23% |
| 2022-12-31 | €33.64 Billion ≈ $39.33 Billion |
€7.00 Billion ≈ $8.18 Billion |
0.208x | +14.89% |
| 2021-12-31 | €31.33 Billion ≈ $36.62 Billion |
€5.67 Billion ≈ $6.63 Billion |
0.181x | +772.92% |
| 2020-12-31 | €28.21 Billion ≈ $32.97 Billion |
€585.19 Million ≈ $684.14 Million |
0.021x | -89.26% |
| 2019-12-31 | €25.99 Billion ≈ $30.38 Billion |
€5.02 Billion ≈ $5.87 Billion |
0.193x | -14.27% |
| 2018-12-31 | €23.14 Billion ≈ $27.06 Billion |
€5.22 Billion ≈ $6.10 Billion |
0.225x | +136.80% |
| 2017-12-31 | €19.26 Billion ≈ $22.52 Billion |
€1.83 Billion ≈ $2.14 Billion |
0.095x | -33.96% |
| 2016-12-31 | €17.65 Billion ≈ $20.64 Billion |
€2.54 Billion ≈ $2.97 Billion |
0.144x | -35.54% |
| 2015-12-31 | €8.68 Billion ≈ $10.15 Billion |
€1.94 Billion ≈ $2.27 Billion |
0.224x | +1.31% |
| 2014-12-31 | €7.92 Billion ≈ $9.26 Billion |
€1.75 Billion ≈ $2.04 Billion |
0.221x | +15.99% |
| 2013-12-31 | €7.02 Billion ≈ $8.21 Billion |
€1.34 Billion ≈ $1.56 Billion |
0.190x | -- |
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, … Read more